COLL Collegium Pharmaceutical Inc

Price (delayed)

$27.01

Market cap

$850.42M

P/E Ratio

12.62

Dividend/share

N/A

EPS

$2.14

Enterprise value

$1.61B

Collegium Pharmaceutical Inc. is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium's headquarters are located in Stoughton, Massachusetts.

Highlights
Collegium Pharmaceutical's gross profit has increased by 16% YoY
The revenue is up by 11% year-on-year and by 5% since the previous quarter
Collegium Pharmaceutical's EPS has increased by 50% YoY but it has decreased by 21% from the previous quarter
The net income has grown by 44% YoY but it has contracted by 22% from the previous quarter
COLL's debt is up by 27% year-on-year
The quick ratio has declined by 23% year-on-year

Key stats

What are the main financial stats of COLL
Market
Shares outstanding
31.49M
Market cap
$850.42M
Enterprise value
$1.61B
Valuations
Price to earnings (P/E)
12.62
Price to book (P/B)
3.81
Price to sales (P/S)
1.38
EV/EBIT
9.35
EV/EBITDA
4.72
EV/Sales
2.55
Earnings
Revenue
$631.45M
Gross profit
$377.34M
Operating income
$166.98M
Net income
$69.19M
EBIT
$172.54M
EBITDA
$341.7M
Free cash flow
$203.33M
Per share
EPS
$2.14
EPS diluted
$1.86
Free cash flow per share
$6.3
Book value per share
$7.1
Revenue per share
$19.57
TBVPS
$18.9
Balance sheet
Total assets
$1.66B
Total liabilities
$1.43B
Debt
$859.3M
Equity
$228.84M
Working capital
-$27.25M
Liquidity
Debt to equity
3.75
Current ratio
0.95
Quick ratio
0.82
Net debt/EBITDA
2.23
Margins
EBITDA margin
54.1%
Gross margin
59.8%
Net margin
11%
Operating margin
26.4%
Efficiency
Return on assets
5.1%
Return on equity
30.7%
Return on invested capital
24.7%
Return on capital employed
15%
Return on sales
27.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

COLL stock price

How has the Collegium Pharmaceutical stock price performed over time
Intraday
-0.04%
1 week
9.49%
1 month
-8.97%
1 year
-23.81%
YTD
-5.72%
QTD
-9.51%

Financial performance

How have Collegium Pharmaceutical's revenue and profit performed over time
Revenue
$631.45M
Gross profit
$377.34M
Operating income
$166.98M
Net income
$69.19M
Gross margin
59.8%
Net margin
11%
The net income has grown by 44% YoY but it has contracted by 22% from the previous quarter
COLL's net margin is up by 29% year-on-year but it is down by 26% since the previous quarter
Collegium Pharmaceutical's operating margin has decreased by 18% QoQ and by 11% YoY
Collegium Pharmaceutical's gross profit has increased by 16% YoY

Growth

What is Collegium Pharmaceutical's growth rate over time

Valuation

What is Collegium Pharmaceutical stock price valuation
P/E
12.62
P/B
3.81
P/S
1.38
EV/EBIT
9.35
EV/EBITDA
4.72
EV/Sales
2.55
Collegium Pharmaceutical's EPS has increased by 50% YoY but it has decreased by 21% from the previous quarter
COLL's P/E is 2.9% below its last 4 quarters average of 13.0
The price to book (P/B) is 22% lower than the last 4 quarters average of 4.9 and 4.8% lower than the 5-year quarterly average of 4.0
The equity is up by 17% year-on-year but it is down by 2.3% since the previous quarter
COLL's price to sales (P/S) is 31% lower than its 5-year quarterly average of 2.0 and 27% lower than its last 4 quarters average of 1.9
The revenue is up by 11% year-on-year and by 5% since the previous quarter

Efficiency

How efficient is Collegium Pharmaceutical business performance
The company's return on assets fell by 29% QoQ but it rose by 24% YoY
The ROE is down by 25% QoQ but it is up by 20% YoY
The ROIC has contracted by 23% from the previous quarter and by 5% YoY
Collegium Pharmaceutical's ROS has decreased by 18% from the previous quarter and by 2.8% YoY

Dividends

What is COLL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for COLL.

Financial health

How did Collegium Pharmaceutical financials performed over time
Collegium Pharmaceutical's total assets is 16% more than its total liabilities
Collegium Pharmaceutical's total liabilities has surged by 51% YoY and by 2.4% QoQ
Collegium Pharmaceutical's total assets has increased by 46% YoY
COLL's debt is up by 27% year-on-year
The equity is up by 17% year-on-year but it is down by 2.3% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.